Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 4:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 70 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo vaginal ring Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring

NCT02006264
View directory record Official record
Conditions
HIV
Interventions
TDF Intravaginal Ring, Placebo Intravaginal Ring
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Phase 2 Interventional Results available

Vaginal Diazepam for the Treatment of Female Pelvic Pain

NCT01938092
View directory record Official record
Conditions
Pelvic Floor Disorders, Pelvic Pain
Interventions
Diazepam, Placebo
Drug
Lead sponsor
Raymond Foster
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Estrogen and the Urogenital Microbiome in GSM

NCT03336437
View directory record Official record
Conditions
Menopause
Interventions
Estradiol vaginal ring, Placebo vaginal ring
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
40 Years to 89 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 22, 2019 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Phase 3 Interventional Results available

Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy

NCT01358760
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Placebo, DHEA
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
32
States / cities
Montgomery, Alabama • Tucson, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 2, 2026, 4:12 AM EDT
Terminated Phase 4 Interventional

Clinical Trial of Solifenacin Versus Placebo Plus Pessary for Women With Vaginal Prolapse

NCT01092624
View directory record Official record
Conditions
Pelvic Organ Prolapse
Interventions
Solifenacin, Placebo, Ring pessary with support, Cooper Surgical, Trumbell, CT Ref # MXPRS03 non-latex
Drug · Device
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 4, 2011 · Synced Oct 2, 2026, 4:12 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Progesterone for Maintenance Tocolysis: A Randomized Placebo Controlled Trial

NCT00946088
View directory record Official record
Conditions
Pregnancy Complications
Interventions
Progesterone, Polyethylene glycol&hydrogenated vegetable oil.
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Phase 3 Interventional Results available

Topical DHEA Against Vaginal Atrophy

NCT01846442
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Placebo, DHEA (0.25%), DHEA (0.5%), DHEA (1.0%)
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Cleveland, Ohio • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Phase 2 Interventional Results available

Randomized Trial Assessing Quinagolide Vaginal Ring for Endometriosis-related Pain

NCT03692403
View directory record Official record
Conditions
Endometriosis-related Pain
Interventions
Quinagolide 360 µg, Quinagolide 720 µg, Quinagolide 1080 µg, Placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
43
States / cities
Mesa, Arizona • Little Rock, Arkansas • San Diego, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 2, 2026, 4:12 AM EDT
Not listed Phase 3 Interventional

Examining Effects of Intrarosa in Women With Genitourinary Syndrome of Menopause/Vulvovaginal Atrophy

NCT03782480
View directory record Official record
Conditions
Menopause, Genitourinary Syndrome of Menopause, Vulvovaginal Atrophy, Menopause Syndrome, Dyspareunia
Interventions
Intrarosa, Placebos
Drug
Lead sponsor
Center for Vulvovaginal Disorders
Other
Eligibility
40 Years to 80 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Oct 2, 2026, 4:12 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Effects of Combined Spinal Epidurals on Fever During Labor of First-Time Mothers

NCT00802646
View directory record Official record
Conditions
Vaginal Delivery
Interventions
saline, fentanyl/bupivacaine/epinephrine
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years to 34 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Phase 3 Interventional Results available

DHEA Against Vaginal Atrophy - 3-Month Efficacy Study

NCT01256684
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Placebo, DHEA
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
24
States / cities
Montgomery, Alabama • Tucson, Arizona • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Vaginal Estrogen on Postpartum Atrophy, Perineal Pain, and Sexual Function

NCT03493126
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Estradiol, Placebo
Drug · Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 22, 2021 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Identification of Novel Biomarkers of Cervicovaginal Mucosal Inflammation

NCT01593124
View directory record Official record
Conditions
Vaginal Inflammation, Vaginal Infections
Interventions
Imiquimod, Placebo, Nonoxynol-9
Drug · Other
Lead sponsor
CONRAD
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 2, 2026, 4:12 AM EDT
Withdrawn Not applicable Interventional

A Study Examining the Use of Vaginal Nifedipine With Pelvic Floor Physical Therapy for Levator Myalgia and Pelvic Pain

NCT01586286
View directory record Official record
Conditions
Levator Ani Syndrome
Interventions
Nifedipine, Placebo Ointment Base
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Phase 3 Interventional Results available

Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause

NCT02013544
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Placebo, Prasterone (DHEA)
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 80 Years · Female only
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
24
States / cities
Montgomery, Alabama • Tucson, Arizona • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)

NCT02237950
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Metronidazole oral tablets 500mg, 1% SPL7013 Gel, Placebo gel
Drug
Lead sponsor
Starpharma Pty Ltd
Industry
Eligibility
16 Years to 45 Years · Female only
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
37
States / cities
Birmingham, Alabama • Montgomery, Alabama • Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Contraception and Menstrual Cycle Effect on Pharmacokinetics, Pharmacodynamics and Safety in Tenofovir Vaginal Gel Use

NCT01421368
View directory record Official record
Conditions
HIV Prevention
Interventions
Tenofovir 1% vaginal gel, Depo-medroxyprogesterone acetate (DMPA), Oral contraceptive: LNG 150 mcg and EE 30 mcg
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 10, 2015 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Phase 2 Interventional Results available

LACTIN-V Study for Recurrent Bacterial Vaginosis

NCT02766023
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Lactobacillus crispatus CTV-05, Metronidazole, Placebo
Biological · Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
San Diego, California • San Francisco, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)

NCT02236156
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Metronidazole oral tablets 500mg, 1% SPL7013 Gel, Placebo gel
Drug
Lead sponsor
Starpharma Pty Ltd
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Phoenix, Arizona • San Diego, California • Metairie, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Oct 2, 2026, 4:12 AM EDT
Withdrawn Phase 3 Interventional

Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study

NCT03619005
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder (HSDD)
Interventions
Placebo Vaginal Insert, Prasterone 6.5 mg (0.50%) Vaginal Insert
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 80 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
10
States / cities
Huntsville, Alabama • San Diego, California • New London, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Phase 3 Interventional Results available

A Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation With a Short Cervix

NCT02518594
View directory record Official record
Conditions
Short Cervical Length
Interventions
Vaginal progesterone, Placebo, Arabin Pessary
Drug · Device
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
Female only
Enrollment
1,311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
16
States / cities
Birmingham, Alabama • San Francisco, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Open-Label, Within-Subject Dose-Escalation Study to Evaluate the Clinical Safety and Pharmacokinetic Profile of a Topical Sildenafil Cream (5% w/w), in Healthy Postmenopausal Women

NCT02364882
View directory record Official record
Conditions
Female Sexual Health
Interventions
Sildenafil
Drug
Lead sponsor
Strategic Science & Technologies, LLC
Industry
Eligibility
35 Years to 65 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Early Phase 1 Interventional

Vaginal lIve Biotherapeutic RANdomized Trial

NCT06135974
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
LC106, LC115, Placebo, Metronidazole Oral
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 2, 2026, 4:12 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Post Operative Continuous Active Combination Sex Steroids for the Prevention of Recurrent Endometrioma Formation

NCT00999479
View directory record Official record
Conditions
Endometrioma
Interventions
Norethindrone acetate and ethinyl estradiol tablets, USP, ferrous fumarate (placebo) tablets
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 35 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Oct 2, 2026, 4:12 AM EDT